ResearcherSalk Institute for Biological StudiesNo recent work listed
Corina E. Antal
Matched on ORCID iD 0000-0002-6174-4930; OpenAlex author ID A5041819909. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 31
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers
Papers 5
- A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Co-author DOI 10.1038/s41467-023-40798-6↗
- Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. Co-author DOI 10.1038/s41467-023-42178-6↗
- Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
- Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. Co-author DOI 10.1038/s41389-020-00285-9↗
- Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-019-1130-6↗
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ronald M. Evans · 5 shared papers, 2019–2023 · strength 0.49
- Paper Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. DOI 10.1038/s41467-023-42178-6↗
- Paper A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. DOI 10.1038/s41467-023-40798-6↗
- Paper Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. DOI 10.1038/s41389-020-00285-9↗
- Daniel D. Von Hoff · 5 shared papers, 2019–2023 · strength 0.49
- Paper Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. DOI 10.1038/s41467-023-42178-6↗
- Paper A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. DOI 10.1038/s41467-023-40798-6↗
- Paper Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. DOI 10.1038/s41389-020-00285-9↗
- Haiyong Han · 3 shared papers, 2020–2023 · strength 0.35
- Paper Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. DOI 10.1038/s41467-023-42178-6↗
- Paper A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. DOI 10.1038/s41467-023-40798-6↗
- Paper Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. DOI 10.1038/s41389-020-00285-9↗
- Gaoyang Liang · 3 shared papers, 2019–2023 · strength 0.28
- Paper Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. DOI 10.1038/s41467-023-42178-6↗
- Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
- Paper Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-019-1130-6↗
- Yu Shi · 3 shared papers, 2019–2023 · strength 0.28
- Paper Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. DOI 10.1038/s41467-023-42178-6↗
- Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
- Paper Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-019-1130-6↗
- Tony R. Hunter · 3 shared papers, 2019–2023 · strength 0.28
- Paper Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. DOI 10.1038/s41467-023-42178-6↗
- Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
- Paper Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-019-1130-6↗
- Andrew M. Lowy · 3 shared papers, 2019–2023 · strength 0.26
- Paper A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. DOI 10.1038/s41467-023-40798-6↗
- Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
- Paper Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-019-1130-6↗
- Erkut Hasan Borazanci · 3 shared papers, 2019–2023 · strength 0.26
- Paper A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. DOI 10.1038/s41467-023-40798-6↗
- Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
- Paper Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-019-1130-6↗
- Dannielle D. Engle · 2 shared papers, 2023 · strength 0.25
- Hervé Tiriac · 2 shared papers, 2023 · strength 0.25
- Serina Ng · 2 shared papers, 2020–2023 · strength 0.23
- Timothy R. Donahue · 2 shared papers, 2019–2021 · strength 0.14
- Kathleen E. DelGiorno · 2 shared papers, 2019–2021 · strength 0.14
- Nikki K. Lytle · 2 shared papers, 2019–2021 · strength 0.14
- Geoffrey Myles Wahl · 2 shared papers, 2019–2021 · strength 0.14
- Maya Ridinger-Saison · 2 shared papers, 2019–2021 · strength 0.14
- Ruilian Xu · 2 shared papers, 2019–2021 · strength 0.14
- Peiwu Huang · 2 shared papers, 2019–2021 · strength 0.14
- Carlos Roberto Becerra · 2 shared papers, 2019–2021 · strength 0.14
- Eric Andrew Collisson · 2 shared papers, 2019–2021 · strength 0.14
- Michael Anthony Hollingsworth · 2 shared papers, 2019–2021 · strength 0.14
- Paul M. Grandgenett · 2 shared papers, 2019–2021 · strength 0.14
- Tannishtha Reya · 2 shared papers, 2019–2021 · strength 0.14
- Ruijun Tian · 2 shared papers, 2019–2021 · strength 0.14
- David J. Propper · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.